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Article Information  ABSTRACT 
Received: 11th Feb 2017  A simple and rapid reversed phase-high performance liquid chromatographic method was 
developed for simultaneous determination of Metformin and Sitagliptin in Tablet Dosage form. 
The elution was done with a mobile phase of Water: Methanol (60:40) on Intersil-BDS C18 
column (250 × 4.6 mm, 5 μm particle size). The wavelength detector was set at 258 nm. 
Retention times for Metformin and Sitagliptin were around 2.869 min, 3.942 min respectively. 
The reliability and analytical performance of the proposed HPLC procedure were statistically 
validated according to the respect of linearity, ranges, precision, accuracy, repeatability, 
reproducibility, detection and quantification limits. Linear ranges were established between 20-
80 μg/mL for both the drug. The LOD and LOQ for Metformin were found to be 0.663, 1.92 
and for Sitagliptin were found to be 0.405, 1.228 respectively. The described High Performance 
Liquid Chromatography method was successfully employed for the analysis of pharmaceutical 
formulations containing combined dosage form 
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INTRODUCTION 
Metformin, chemically 1-carbamimidamido-N, N dimethyl 
methanimidamide (Fig. 1) is a biguanide antihyperglycemic 
agent used for treating non insulin dependent diabetes mellitus 
(NIDDM). It improves glycemic control by decreasing hepatic 
glucose production, decreasing glucose absorption and 
increasing insulin-mediated glucose uptake.[1-2]. Metformin is 
the only oral antihyperglycemic agent that is not associated 
with weight gain. Metformin may induce weight loss and is the 
drug of choice for obese NIDDM patients.[3] When used alone, 
metformin does not cause hypoglycaemia; however, it may 
potentiate the hypoglycaemic effects of sulfonylurea and 
insulin. Its main side effects are dyspepsia, nausea and 
diarrhoea. Metformin decreases fasting plasma glucose, 
postprandial blood glucose and glycosolated hemoglobin 
(HbA1c) levels, which are reflective of the last 8-10 weeks of 
glucose control. Metformin may also have a positive effect on 
lipid levels. [4-5] 
Sitagliptin is a new oral hypoglycaemic of the new dipeptidyl 
peptidase-4 (DPP-4) inhibitor class of drugs. This enzyme-
inhibiting drug is to be used either alone or in combination with 
metformin or a thiazolidinedione for control of type 2 diabetes 
mellitus. The drug works to competitively inhibit a protein/ 
enzyme, dipeptidyl peptidase 4 (DPP-4), that results in an 
increased amount of active incretins (GLP-1 and GIP), reduced 
amount of release of glucagon (diminishes its release) and 
increased release of insulin.[6-8] Several analytical methods 
based on UV, [9-12] HPLC, [13-14] and HPTLC [15] were 
reported for the determination of Metformin. Few analytical 
methods based on UV, [16-17] RP-HPLC, [18] were reported 
for the determination of Sitagliptin. Simultaneous 
determination of Metformin and Sitagliptin in bulk and tablet 
dosage form were reported by using spectrophotometric, [19] 
spectroflourometric[20] and HPLC[21] methods. However very 
few HPLC methods were reported for the simultaneous 
estimation of Metformin and Sitagliptin in tablet dosage form. 
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The objective of this study was to develop a simple, specific, 
accurate, precise, sensitive RP-HPLC method for the 
determination of Metformin and Sitagliptin in bulk and 
pharmaceutical dosage forms. This method was validated in 
accordance with ICH guidelines. [22] 
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Fig 1: Metformin Fig 2: Sitagliptin
 
MATERIALS AND METHODS 
Instruments 
Chromatographic separation was performed using HPLC-
WATERS Model NO.2690/5 equipped with PDA detector. 
Intersil C18 column (250×4.6 mm, 5μm particle size) was used. 
 
Reagents and materials 
All chemicals substances were of analytical reagent grade and 
solvents were of HPLC grade.  
 
Chromatographic conditions 
Chromatographic separation was performed on a Chromosil 
Intersil C18 column (250 × 4.6 mm, 5 μm particle size) . The 
mobile phase consisted of water and methanol in ratio 60: 40 
were filtered before use through a 0.45 μ membrane and 
degassed for 10 min. The flow rate was 1 mL/min and the 
column temperature was maintained at 27°C.The volume of 
injection was 20 μl. The UV detector was set up at 258 nm. 
 
Preparation of standard stock solution 
 Accurately weigh and transfer 100 mg of Metformin and 10 
mg of Sitagliptin working standards into a 100 ml clean dry 
volumetric flask, add about 10 ml of mobile phase and make 
volume up to the mark with the mobile phase. Further pipette 
out 1 ml from above stock solution into 10 ml volumetric flask 
and dilute up to the mark with mobile phase. 
 
Preparation of sample solutions 
Twenty tablets were weighed and finely powdered. A quantity 
of powder equivalent to 50 mg of Sitagliptin and 500 mg of 
Metformin of the tablet formulation was weighed accurately 
and transferred to a 100 ml volumetric flask. In RP-HPLC, to 
this solution 50 ml mobile phase was added and sonicated for 
10 min and then final volume was made up to the mark with 
mobile phase. The resulting solution was filtered through 
Whatmann filter paper no 41, and the filtrate was appropriately 
diluted to get desired concentration of Sitagliptin and 
Metformin  which was required for analysis. 
 
RESULTS AND DISCUSSION 
Method optimisation 
A simple reverse phase high performance liquid 
chromatography method was developed for the determination 
of Metformin and Sitagliptin in pure form and in 
pharmaceutical formulations using Chromosil Intersil C18 
column (250 × 4.6 mm, 5 μm particle size). The mobile phase 
consisted of water and methanol in ratio 60:40. The mobile 
phase was chosen after several trials to reach the optimum 
stationary /mobile phase matching. The flow rate is 1.0ml/min. 
The average retention times under the conditions described 
were 2.869 min, 3.942 min for Metformin and Sitagliptin 
respectively (Table 1, Fig.3).  
Table 1: Optimised Method 
Parameters Method 
Stationary phase (column) 
Inertsil -BDS C18(250 x 4.6 
mm, 5 µ) 
Mobile Phase Methanol : water(40:60) 
Flow rate (ml/min) 1.0 ml/min 
Run time (minutes) 10 min 
Column temperature (°C) Ambient 
Volume of injection loop (l) 20 
Detection wavelength (nm) 258 nm 
Drug RT (min) 
2.8min for Metformin and 
3.9for Sitagliptin 
 
Fig. 3: Optimised Chromatogram 
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System Suitability 
The resolution, capacity factor, theoretical plates/meter, Rt 
values and peak symmetry were calculated for the standard 
solutions. The values (Table 2) obtained demonstrated the 
suitability of the system for the analysis of the above drug 
combinations.  
 
Linearity 
The linearity of the method was determined by Preparing serial 
dilutions of minimum 5 concentration of standard stock 
solutions each in duplicate. Take the average area of each 
injection and plot the graph of average peak area versus actual 
concentration of each solution in μg/ml. Linearity ranges were 
found to be 20-80 μg/mL for both the drugs (Fig. 4,5). 
 
Table 2: System suitability 
Parameters Metformin Sitagliptin Acceptance 
Criteria 
USP Tailing 1.07 1.59 NMT 2.0 
USP Plate count 9478 10768 NLT 2000 
% RSD of peak Areas 0.01 0.04 NMT 2.0 
Retention time 2.868 3.942 ---- 
 
 Table 3: Accuracy data 
Accuracy level  Mean recovery of 
Metformin % 
Mean recovery of 
Sitagliptin % 
Accuracy 50% 99.69 100.06 
Accuracy 100% 99.83 100.04 
Accuracy 150% 99.97 100.02 
 
Accuracy and precision 
The accuracy of the method was determined by recovery 
experiments which were carried out and the percentage 
recovery and % relative standard deviation was calculated. 
From the data obtained, recoveries of standard drugs were 
found to be accurate (Table 3).The precision was carried out 
for System precision, Method precision and Intermediate 
precision (Table 4). 
 
Specifity of the method. 
In formulations, chromatograms with some additional peaks 
were observed which may be due to excipients present in the 
formulations. These peaks however did not interfere with the 
standard peaks .The results revealed that the peak is free from 
interferences, which shows that the HPLC method is specific. 
Table 4: Precision 
Analyte System precision Method precision Intermediate precision 
Peak area ± SD % RSD Peak area ± SD % RSD Peak area ± SD % RSD 
Metformin 2705542 ± 739.0046 0.027314 2701851 ± 729.2689 0.026991 2706167 ± 2306.932 0.085247 
Sitagliptin 1744318 ± 8241.164 0.472458 1731322 ± 5988.879 0.345914 1744608 ± 8392.59 0.481059 
 
Fig.  4: Linearity of Metformin  
 
 
Fig. 5: Linearity of Sitagliptin 
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Fig 6: Flow rate for 0.8 ml/min 
 
Fig 7: Flow rate for 1.2 ml/min 
 
Table 5: Robustness 
Parameters 
% RSD 
Metformin Sitagliptin 
0.8ml/min 0.11 0.06 
1.2ml/min 0.35 0.09 
 
Quantification Limit 
The LOD is the lowest concentration of the analyte that can be 
detected with signal to noise ratio (1:3) and LOQ is the lowest 
concentration that can be quantified with acceptable precision 
and accuracy with signal to noise ratio (1:10). The LOD of 
Metformin and Sitagliptin are found to be 0.633μg/ml and 
0.405μg/ml respectively. The LOQ of Metformin and 
Sitagliptin are found to be 1.92μg/ml 1.23μg/ml respectively. 
 
Robustness 
The robustness of the method was studied by changes in the 
method like alteration in flow rate (0.2 ml/min of set value i.e. 
0.8 ml/min and 1.2 ml/min), detection are evaluated (Table 5, 
Fig 6,7). 
 
CONCLUSION 
The proposed method was found to be simple, precise, accurate 
and rapid for simultaneous determination of Metformin and 
Sitagliptin and from pure pharmaceutical formulations. The 
mobile phase is simple to prepare and the run time was less 
than 5min which consumes only less than 5ml of mobile Phase 
shows that the method was economical.  
 
The sample recoveries in all formulations were in good 
agreement with their respective label claims suggested non-
interference in the estimation. Hence, the method can be easily 
and conveniently adopted for routine analysis of Metformin 
and Sitagliptin in combined dosage forms. The simplicity 
ensures that the RP-HPLC method can be applied for 
estimation of Metformin and Sitagliptin in tablet dosage forms. 
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Since the good separation and resolution of the 
chromatographic peaks, the method was found to be accurate, 
precise, linear, robust and rugged.  
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